Enzalutamide + Leuprolide Top for Mets-Free Survival in Prostate Cancer

WEDNESDAY, Oct. 18, 2023 -- For patients with prostate cancer with high-risk biochemical recurrence, enzalutamide plus leuprolide is best for metastasis-free survival, according to a study published in the Oct. 19 issue of the New England Journal of...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news